Similar articles

• Behavioral outcomes in clinical trials for Alzheimer disease.

  Ferris SH, Mackell JA. Ferris SH, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S10-5. Alzheimer Dis Assoc Disord. 1997. PMID: 9339267 Review.
• The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

  Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM. Bodick NC, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S16-22. Alzheimer Dis Assoc Disord. 1997. PMID: 9339268 Clinical Trial.
• [Challenging pharmacotherapy in dementia].

  Ihl R. Ihl R. MMW Fortschr Med. 2009 Mar 26;151(13):46-8. MMW Fortschr Med. 2009. PMID: 19504818 German. No abstract available.
• Dementia.

  Warner J, Butler R. Warner J, et al. Clin Evid. 2002 Jun;(7):846-66. Clin Evid. 2002. Update in: Clin Evid. 2002 Dec;(8):927-50. PMID: 12230710 Updated. Review. No abstract available.
• Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia.

  Chibnall JT, Tait RC, Harman B, Luebbert RA. Chibnall JT, et al. J Am Geriatr Soc. 2005 Nov;53(11):1921-9. doi: 10.1111/j.1532-5415.2005.53572.x. J Am Geriatr Soc. 2005. PMID: 16274373 Clinical Trial.